Failure to Achieve a PSA Level ≤1 ng/mL After Neoadjuvant LHRHa Therapy Predicts for Lower Biochemical Control Rate and Overall Survival in Localized Prostate Cancer Treated With Radiotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 69, Issue 5, 2007, Pages 1467-1471

  Mitchell, Darren M ^a   McAleese, Jonathan ^a   Park, Richard M ^a   Stewart, David P ^a   Stranex, Stephen ^a   Eakin, Ruth L ^a   Houston, Russell F ^a   O'Sullivan, Joe M ^a,b  

^a BELFAST CITY HOSPITAL   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Neoadjuvant hormonal therapy; Prostate cancer; Prostate specific antigen; PSA; Radiotherapy

Indexed keywords

BIOCHEMICAL ENGINEERING; BIOLOGICAL ORGANS; CELLS; HORMONES; TUMORS;

NEOADJUVANT HORMONAL THERAPY; PROSTATE CANCER; PROSTATE SPECIFIC ANTIGEN;

RADIOTHERAPY;

GONADORELIN ANTAGONIST; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DRUG TREATMENT FAILURE; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; FOLLOW-UP STUDIES; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; REFERENCE VALUES; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 36148977180     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.05.008     Document Type: Article

References (18)

1. Pilepich M.V., Winter K., John M.J., et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50 (2001) 1243-1252
2. Hanks G.E., Pajak T.F., Porter A., et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group protocol 92-02. J Clin Oncol 21 (2003) 3972-3978
3. D'Amico A.V., Manola J., Loffredo M., et al. 6-Month androgen suppression plus radiation therapy vs. radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 292 (2004) 821-827
4. Roach III M., DeSilvio M., Lawton C., et al., the Radiation Therapy Oncology Group 9413. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression. J Clin Oncol 21 (2003) 1904-1911
5. Zietman A.L., Tibbs M.K., Dallow K.C., et al. Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T l-2 adenocarcinoma of the prostate. Radiother Oncol 40 (1996) 159-162
6. Pollack A., Smith L.G., and von Eschenbach A.C. External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. Int J Radiat Oncol Biol Phys 48 (2000) 507-512
7. Ludgate C.M., Bishop D.C., Pai H., et al. Neoadjuvant hormone therapy and external-beam radiation for localized high-risk prostate cancer: The importance of PSA nadir before radiation. Int J Radiat Oncol Biol Phys 62 (2005) 1309-1315
8. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
9. Roach M., Hanks G., Thames H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
10. Sarosdy M.F., Schellhammer P.F., Soloway M.S., et al. Endocrine effects, efficacy and tolerability of a 10.8mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer. BJU Int 83 (1999) 801-806
11. Crook J., Ludgate C., Malone S., et al. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 60 (2004) 15-23
12. Niblock P., and Pickles T. Rising prostate-specific antigen values during neo-adjuvant androgen deprivation therapy: The importance of monitoring. Int J Radiat Oncol Biol Phys 65 (2006) 59-64
13. Sumi M., Ikeda H., Tokuuye K., et al. The external radiotherapy with three-dimensional conformal boost after the neoadjuvant androgen suppression for patients with locally advanced prostatic carcinoma. Int J Radiat Oncol Biol Phys 48 (2000) 519-528
14. Zelefsky M.J., Lyass O., Fuks Z., et al. Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy. J Clin Oncol 16 (1998) 3380-3385
15. Heymann J.J., Benson M.C., O'Toole K.M., et al. Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer. J Clin Oncol 25 (2007) 77-84
16. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41 (1998) 491-500
17. Brenner D.J., Martinez A.A., Edmundson G.K., et al. Direct evidence that prostate cancer tumors show high sensitivity to fractionation (low α/β ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phy 52 (2002) 6-13
18. Yeoh E.E., Holloway R.H., Fraser R.J., et al. Hypofractionated versus conventional fractionated radiation therapy for prostate carcinoma: Undated results of a phase 3 randomised trial. Int J Radiat Oncol Biol Phy 66 (2006) 1072-1083